FDG PET Myocardial Viability Imaging

FDG PET myocardial viability imaging answers one decisive question before revascularization: is the dysfunctional heart muscle dead scar, or is it hibernating tissue that can recover? By imaging glucose metabolism with F-18 fluorodeoxyglucose and comparing it to blood flow, the study identifies a perfusion–metabolism mismatch—reduced flow with preserved metabolism—that marks viable, salvageable myocardium.

Patients with ischemic cardiomyopathy and a severely reduced left ventricular ejection fraction face high surgical risk from revascularization. The decision to proceed rests on whether enough dysfunctional myocardium is viable to justify that risk. FDG PET is the metabolic reference standard for making that call, and its physics—and its demanding patient preparation—are what make it work. ¹

This article explains the metabolic basis of viability imaging, the F-18 and PET physics behind it, the glucose-loading protocols that determine image quality, how mismatch is interpreted and quantified, and the physics and regulatory oversight a cardiac PET program needs. DRPS supports these programs through PET/CT and nuclear medicine physics services.

Introduction

Viable but dysfunctional myocardium comes in two forms—stunned and hibernating—and both can recover contractile function if blood flow is restored. Hibernating myocardium is the central target of viability imaging: chronically underperfused muscle that has down-regulated contraction to survive, remaining metabolically active but mechanically silent. ⁵⁶

The insight that metabolism, not motion, reveals viability dates to the 1980s. Tillisch and colleagues showed with PET using N-13 ammonia for flow and F-18 FDG for metabolism that preserved glucose uptake in akinetic segments predicted recovery of wall motion after bypass surgery, with high predictive accuracy, while the electrocardiogram predicted poorly. ⁴ That flow–metabolism paradigm remains the foundation of cardiac viability PET today. ¹

Because a hibernating segment is alive but not contracting, no measurement of resting function can distinguish it from scar. Only a metabolic probe can, and FDG—a glucose analog taken up in proportion to glucose utilization—is that probe. ⁶

Topic Explanation

The metabolic basis of viability

The healthy, well-oxygenated myocardium preferentially burns free fatty acids. Under ischemia, oxidative fatty-acid metabolism is impaired and the myocyte shifts toward anaerobic and glucose metabolism, increasing glucose uptake relative to perfusion. ⁶ FDG is transported into the cell like glucose and phosphorylated by hexokinase to FDG-6-phosphate, which is then effectively trapped because it is not a substrate for the next glycolytic step. This metabolic trapping is what lets PET image regional glucose utilization. ¹⁶

The consequences for interpretation are direct:

• A dysfunctional region with reduced flow but preserved or increased FDG uptake is metabolically active—viable, hibernating myocardium.
• A dysfunctional region with reduced flow and reduced FDG uptake has lost metabolic activity—scar.

Pairing metabolism with perfusion

Viability imaging is inherently a two-tracer comparison. FDG metabolism is read alongside a myocardial blood-flow image, obtained with a PET perfusion tracer such as N-13 ammonia or rubidium-82, or with a Tc-99m SPECT perfusion study. ¹ The paired images are co-registered and scored segment by segment on a standard left-ventricular model.

The flow–metabolism mismatch—reduced flow with maintained FDG—is the signature of hibernating myocardium and the pattern most strongly associated with recovery after revascularization. ¹⁵

Key Technical Principles

F-18 and the physics of PET detection

FDG is labeled with fluorine-18, a positron (β⁺) emitter. According to standard nuclear decay data, F-18 has a physical half-life of about 109.8 minutes and decays predominantly by positron emission. ⁹ An emitted positron travels a short distance in tissue, loses energy, and annihilates with an electron. The annihilation converts the rest mass of the two particles into two photons emitted almost exactly back-to-back, each carrying the electron rest-mass energy:

PET detects these two 511 keV photons in coincidence—a valid event is recorded only when two detectors register photons within a narrow timing window along a line of response. This coincidence requirement is what gives PET its sensitivity and its superior quantification compared with single-photon imaging. ¹

The 109.8-minute half-life governs scheduling and dosimetry. Activity decays as:

For FDG, $\lambda =\ln 2/109.8\min \approx 6.31\times 10^{-3}{\min }^{-1}$. Over a typical 45-minute uptake period between injection and imaging, the fraction of activity remaining is:

so roughly three-quarters of the injected activity remains at the start of acquisition. The short half-life means doses must be assayed and administered promptly, and it constrains how many patients a single FDG delivery can serve.

Quantifying viability

Viability is read from relative FDG uptake and from the extent of mismatch. Regional FDG activity is commonly normalized to the segment with maximum uptake and expressed as a percentage; a dysfunctional segment retaining uptake above a threshold (commonly in the region of 50% of maximum) is generally considered viable, though exact thresholds depend on the protocol and laboratory. ¹⁶ Across the ventricle, the number of dysfunctional-but-viable (mismatched) segments—the extent of hibernating myocardium—carries the prognostic weight: the larger the viable territory, the greater the expected benefit from restoring flow. ³⁵

Why patient preparation dominates image quality

The single greatest determinant of a diagnostic viability study is metabolic substrate preparation. Under fasting conditions the myocardium burns fatty acids and takes up little FDG, so normal and hibernating muscle alike image poorly. The goal of preparation is a state of euglycemia with hyperinsulinemia at the time of FDG injection, because insulin drives glucose—and therefore FDG—into myocytes. ¹

The procedure standard describes the common approaches: ¹

• Oral glucose loading with supplemental insulin. After a fast (commonly 6–12 hours), an oral glucose load (on the order of 25–100 g) is given, blood glucose is monitored, and intravenous insulin is added as needed to bring glucose into the target range. This is the most widely used method.
• Euglycemic hyperinsulinemic clamp. A continuous, controlled infusion of insulin and glucose produces the most consistent myocardial FDG uptake and the best image quality, at the cost of greater complexity and labor.
• Nicotinic acid derivatives. Agents that suppress plasma free fatty acids can enhance myocardial FDG uptake and are used in some protocols.

Diabetic patients are the hardest case: impaired insulin responsiveness means standard loading often yields poor uptake, requiring more supplemental insulin, closer glucose monitoring, and sometimes a clamp. Careful attention to the protocol—documented blood-glucose values and insulin dosing—is not a formality; it is the difference between an interpretable study and an uninterpretable one.

Clinical Impact

Viability imaging exists to inform a high-stakes decision: revascularize a patient with a severely impaired ventricle, or manage medically. The evidence base is substantial and nuanced.

• Observational data and meta-analysis. A pooled meta-analysis of viability studies (thallium, FDG, and dobutamine echocardiography) in patients with coronary disease and LV dysfunction found that, among patients with viability, revascularization was associated with a large reduction in annual mortality compared with medical therapy (3.2% vs 16%), whereas patients without viability showed no such benefit. ³ This established the strong association between demonstrated viability and survival benefit from revascularization.
• Randomized trial (PARR-2). The PET and Recovery Following Revascularization-2 trial randomized patients with severe LV dysfunction to FDG PET-assisted management versus standard care. The primary composite outcome was not significantly reduced overall, but significant benefit emerged in patients who adhered to the PET recommendations and in those without recent angiography. ² The practical message is that viability imaging helps most when its results are actually acted upon.
• STICH viability substudy. In the surgical-revascularization STICH trial, the presence of viable myocardium was associated with better outcome on unadjusted analysis but not after adjustment for other variables, and viability status did not identify a subgroup with a differential survival benefit from surgery versus medical therapy. ¹⁰ This tempered the earlier observational enthusiasm and reinforced that viability is one factor among many.

The consensus reflected in the procedure standard is that FDG PET viability imaging is a valuable input into a multidisciplinary revascularization decision for selected patients with ischemic cardiomyopathy—not a stand-alone gatekeeper. ¹

Practical Optimization Tips

• Standardize the glucose–insulin protocol and record blood-glucose values and insulin doses for every patient; treat preparation as the primary quality-control step, with a tailored pathway for diabetics. ¹
• Always pair FDG with a perfusion image and co-register carefully—viability is a comparison, and mis-registration between flow and metabolism creates false mismatch or match patterns. ¹
• Report extent, not just presence. Quantify how much dysfunctional myocardium is viable; the size of the mismatch is what drives prognosis and the revascularization conversation. ³⁵
• Mind the 109.8-minute half-life. Assay and administer promptly, coordinate delivery timing, and keep uptake times consistent so quantification is comparable across patients.
• Keep the scanner quantitative. Daily QC, accurate normalization and attenuation correction, and a well-calibrated dose calibrator are prerequisites for reliable relative-uptake thresholds; see PET/CT daily QC and calibration and PET/CT attenuation correction.

Regulatory Considerations

FDG is a byproduct material, and cardiac PET programs operate under medical-use radiation regulations plus imaging-accreditation requirements. The physics and safety program should be documented and overseen by qualified personnel.

Key frameworks:

• ASNC/SNMMI PET nuclear cardiology procedure standard defines acquisition, patient preparation, and interpretation expectations for cardiac FDG and perfusion PET. ¹
• 10 CFR Part 35 (Medical Use of Byproduct Material) governs authorized use of F-18 FDG; routine diagnostic FDG imaging is administered under the unsealed-byproduct provisions and ordinarily does not require a written directive, unlike therapy administrations.
• 10 CFR Part 20 (Standards for Protection Against Radiation) sets the occupational and public dose limits that shape shielding and workflow around 511 keV photons, which are far more penetrating than the 140 keV photons of Tc-99m.
• ICRP Publication 107 provides the F-18 nuclear decay data used for dosimetry. ⁹

Jurisdiction depends on location. Across the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that administer medical use through their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC for radioactive material. A facility should verify which authority issues and inspects its license. The elevated staff dose from 511 keV work is a recurring theme in PET safety and warrants occupational-dose attention. For program support, see medical physicist consulting.

Frequently Asked Questions (FAQs)

What does FDG PET myocardial viability imaging show?

It images glucose metabolism in the heart muscle with F-18 fluorodeoxyglucose (FDG) and compares it to myocardial blood flow. Dysfunctional regions that still take up FDG despite reduced flow are viable (hibernating) and may recover function after revascularization; regions with both reduced flow and reduced FDG are scar.

What is hibernating myocardium?

Hibernating myocardium is heart muscle with chronically reduced blood flow that has down-regulated its contraction to survive. It is dysfunctional but alive, shifts toward glucose metabolism, and can recover contractile function if blood flow is restored by revascularization.

Why do patients need glucose and insulin before cardiac FDG PET?

Under fasting conditions the heart burns fatty acids and takes up little FDG, giving poor images. A glucose load, usually with supplemental insulin to reach euglycemia and hyperinsulinemia, shifts the myocardium to glucose metabolism so that normal and hibernating muscle take up FDG and image well. Diabetic patients often need more insulin and careful glucose monitoring.

What is a perfusion–metabolism mismatch?

A mismatch is reduced myocardial blood flow with preserved or increased FDG uptake in the same region. It indicates viable, hibernating myocardium. A match—reduced flow and reduced FDG together—indicates scar. Mismatch is the hallmark of tissue likely to benefit from revascularization.

How is viability quantified on FDG PET?

Viability is assessed from relative FDG uptake, often expressed as a percentage of the segment with maximum uptake, and from the extent of flow–metabolism mismatch across the left ventricle. Larger amounts of mismatched (viable) dysfunctional myocardium predict a greater chance of functional recovery and benefit from revascularization.

Does FDG PET viability imaging improve outcomes?

Observational data and a meta-analysis link detection of viability plus revascularization to better survival, while randomized trials (PARR-2 and the STICH viability substudy) showed more nuanced results. Viability imaging is best used as one input into a multidisciplinary revascularization decision, not as a sole determinant.

Who oversees the physics and safety of a cardiac PET program?

A qualified or board-certified medical physicist supports scanner quality control, dose-calibrator accuracy, image quantification, radiation safety for 511 keV photons, and accreditation. FDG is a byproduct material regulated under NRC or Agreement State medical-use rules.

Key Takeaways

• Metabolism reveals viability. Hibernating myocardium is dysfunctional but alive; only a metabolic probe like FDG can distinguish it from scar. ⁴⁶
• Mismatch is the signature. Reduced flow with preserved FDG uptake marks viable, salvageable muscle; matched flow and metabolism defects mark scar. ¹⁵
• Preparation is everything. Euglycemia with hyperinsulinemia—via oral glucose plus insulin or a clamp—drives myocardial FDG uptake; diabetics need special handling. ¹
• Physics underpins quantification. Coincidence detection of 511 keV annihilation photons and a 109.8-minute half-life govern image quality, scheduling, and dosimetry. ⁹
• Evidence is nuanced. Observational and meta-analytic data favor viability-guided revascularization, while RCTs (PARR-2, STICH) show benefit is conditional—use viability as one input. ²³¹⁰

Conclusion

FDG PET myocardial viability imaging turns a question that resting function cannot answer—dead scar or recoverable muscle?—into a metabolic image with real prognostic weight. The flow–metabolism mismatch is the physiologic fingerprint of hibernating myocardium, and detecting it can identify patients most likely to benefit from the risks of revascularization. ¹⁵

Delivering a trustworthy study demands discipline on both ends: rigorous glucose–insulin preparation so the metabolic signal is there to measure, and a quantitatively sound PET program so the measurement is reliable. When preparation, perfusion pairing, and quantification are done well—and the result is interpreted as one input into a multidisciplinary decision—FDG PET viability imaging remains the metabolic reference standard in ischemic cardiomyopathy.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and PET programs with PET/CT and nuclear medicine physics services: scanner acceptance testing and quality control, dose-calibrator and quantification oversight, attenuation-correction and normalization review, radiation safety for 511 keV photon work, and medical physicist consulting for accreditation and protocol optimization.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. A cardiac PET program is only as good as its quantification and its patient preparation—contact us through our contact page to review both.

Related Resources

• N-13 ammonia cardiac PET perfusion
• Tc-99m sestamibi/tetrofosmin myocardial perfusion SPECT
• PET SUV quantification
• PET/CT attenuation correction
• Common PET & RPT isotopes
• PET/CT and nuclear medicine physics
• Medical physicist consulting

References

1. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23(5):1187-1226. doi:10.1007/s12350-016-0522-3. PubMed
2. Beanlands RSB, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50(20):2002-2012. doi:10.1016/j.jacc.2007.09.006. PubMed
3. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151-1158. doi:10.1016/s0735-1097(02)01726-6. PubMed
4. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884-888. doi:10.1056/NEJM198604033141405. PubMed
5. Allman KC. Noninvasive assessment myocardial viability: current status and future directions. J Nucl Cardiol. 2013;20(4):618-637. doi:10.1007/s12350-013-9737-8. PubMed
6. Bax JJ, Visser FC, van Lingen A, Cornel JH, Fioretti PM, van der Wall EE. Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. Int J Card Imaging. 1997;13(2):145-155. doi:10.1023/a:1005744810876. PubMed
7. Schinkel AFL, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375-410. doi:10.1016/j.cpcardiol.2007.04.001. PubMed
8. American Society of Nuclear Cardiology. Imaging Guidelines for Nuclear Cardiology Procedures: PET myocardial perfusion and metabolism clinical imaging. asnc.org
9. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
10. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617-1625. doi:10.1056/NEJMoa1100358. PubMed